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ABSTRACT 
Backgrounds: An early and transient verbal fluency (VF) decline and impairment in frontal 
executive function, suggesting a cognitive microlesion effect may influence the cognitive 
repercussions related to subthalamic nucleus deep brain stimulation  (STN-DBS.) 
Methods:  Neuropsychological tests including semantic and phonemic verbal fluency were 
administered both before surgery (baseline), the third day after surgery (T3), at six months 
(T180), and at an endpoint multiple years after surgery (Tyears). 
Results: Twenty-four patients (mean age, 63.5 ± 9.5 years; mean disease duration, 12 ± 5.8 
years) were included. Both semantic and phonemic VF decreased significantly in the acute 
post-operative period (44.4 ± 28.2 and 34.3 ± 33.4, respectively) and remained low at 6 
months compared to pre-operative levels (decrease of 3.4 ± 47.8% and 10.8 ± 32.1%) (P < 
0.05). Regression analysis showed phonemic VF to be an independent factor of decreased 
phonemic VF at six months. Age was the only independent predictive factor for incident 
Parkinson's disease dementia (PDD) (F (4,19) = 3.4, P <0.03). 
Conclusion: An acute post-operative decline in phonemic VF can be predictive of a long-
term phonemic VF deficit. The severity of this cognitive lesion effect does not predict the 
development of dementia which appears to be disease-related. 
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Introduction 
 Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in selected patients 
with advanced Parkinson's disease (PD) has been shown to improve motor symptoms and 
quality of life [1]. Even though the procedure is not considered to cause major cognitive side-
effects, it is associated with changes in executive function, in particular decreased verbal 
fluency (VF) [2]. Several factors are thought to predict cognitive decline following STN-
DBS, such as advanced age, axial signs, levodopa resistant symptoms, visual hallucinations, 
vascular lesion load, and poor baseline cognitive performance [3-4]. Higher formal education, 
higher levodopa equivalent dose, and younger age at onset also correlate with cognitive 
worsening after STN-DBS in PD [5].  
 A surgical motor microlesion effect appearing in the immediate post-operative period 
has been shown to be predictive of motor improvement 6 months after STN-DBS [6]. 
Similarly, an early and transient VF decline and impairment in frontal executive function has 
been described, suggesting a cognitive microlesion effect that may be partly responsible for 
the cognitive repercussions related to STN-DBS [7-9]. Whether this early cognitive 
impairment influences long-term cognitive performances and the incidence of Parkinson's 
disease dementia (PDD) after STN-DBS remains unknown. 
 In this study, we evaluated VF in 26 consecutive PD at baseline, in the immediate 
post-operative period prior to activating the pulse generator, 6 months after surgery, and at the 
end of the observation period (up to eight years after surgery.) We assessed whether the 
decline in VF present immediately after STN-DBS could be predictive of VF assessed 6 
months after surgery and the apparition of PDD years after the surgery.   
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Materials and Methods 
 
Patients  
 Twenty-six consecutive patients (mean age, 57.9 ± 8.5 years; range, 37–79 years) with 
advanced levodopa-responsive PD (Hoehn and Yahr score ≥ 3; mean disease duration, 11.4 ± 
3.5 years; range, 5 –19 years) referred for STN stimulation were enrolled. The selection 
criteria were clinically diagnosed PD, severe levodopa-related complications despite optimal 
adjustment of antiparkinsonian medication, no surgical contraindications, and no dementia or 
major ongoing psychiatric illness.  
 
Surgical Procedure and Post-operative Management 
The surgical procedure has been previously described [10]. All recordings were 
performed on five parallel trajectories. The definitive quadripolar electrode (DBS type 3389, 
Medtronic, Minneapolis, Mn, USA) was positioned so that at least two contacts were located 
within the STN according to the best perioperative electrophysiological recordings and motor 
improvement and the fewest side effects. During the same session, the whole procedure was 
repeated to implant the contralateral STN. The day following the STN implantation, the 
programmable pulse generator (Kinetra, Medronic) was implanted under general anesthesia 
in the subclavicular region. All the patients gave their informed consent to their participation 
in the study and the protocol was approved by our local ethic committee. 
 
Neuropsychological testing 
 Neuropsychological testing, i.e. the Mattis Dementia Rating Scale (MDRS), the Stroop 
test, free and cued recall, the Wisconsin card sorting test, digit and spatial spans, serial 
ordering, and MMS were administrated both before surgery (baseline), after surgery at six 
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months (T180), and at an endpoint multiple years after surgery (Tyears). The final evaluation 
occurred in 2012 or 2013 if no earlier proof of PDD was available. Semantic (animal names) 
and phonemic (words beginning with “p”) VF performances were evaluated both before 
surgery (baseline) and, after surgery the third day (T3), at six months (T180), and at an 
endpoint multiple years after surgery (Tyears). 
 The baseline cognitive evaluation was performed one month before the intervention, in 
the on-drug condition. At T3, the cognitive evaluation was performed in the off- condition, 
i.e. 12 h withdrawal of dopaminergic treatment and with the programmable pulse generator 
switched off (off-drug/ off-stimulation). The six-month (T180) post-operative cognitive and 
the at-distance evaluations were performed in the on-drug/ on-stimulation condition.  
 In addition, dementia analyses were conducted using the criteria established by Emre 
et al.[11] and DSM-IV-TR [12] independently to identify participants who met criteria for 
PDD, i.e. a dementia syndrome with insidious onset and slow progression, developing within 
the context of established Parkinson's disease and diagnosed by history, clinical, and mental 
examination defined as: impairment in more than one cognitive domain; representing a 
decline from premorbid level; deficits severe enough to impair daily life (social, occupational, 
or personal care), independent of the impairment ascribable to motor or autonomic symptoms. 
The patients were assessed with the Confusion Assessment Method (CAM) after 
surgery at T3, and T180; a score of CAM > 2/4 was considered as a confusional state [13].  
 
Motor Evaluation 
Clinical evaluations were performed one month before and six months after surgery. 
Motor performance and complications of levodopa therapy were assessed using the UPDRS 
parts III, and IV, respectively. The percentage of motor improvement was determined in 
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comparison to the preoperative off-drug condition. All dopaminergic drugs, expressed in 
dopa-equivalent daily dose, were recorded before and after surgery.  
 
Statistical analysis 
The different scores were expressed as mean value  SD. Scores obtained before 
surgery (baseline on-state) were compared with scores at T3 and T180 after surgery using an 
analysis of variance for repeated measures (ANOVA). VF decline was defined as the 
percentage of reduction (total number of words) between baseline and T3. 
Baseline MDRS score, age at the time of DBS, and percentage of VF decline (total 
number of words) were included in a multiple regression to determine: i) firstly, which were 
predictive of the VF assessed six months after surgery; ii) secondly, which were predictive of 
the occurrence of PDD years after surgery. 
Statistical analysis was performed with the STATISTICA version 7.1, StatSoft1, 
France.   
 
Results 
 Twenty-four patients (mean age, 63.5 ± 9.5 years; range, 36 – 79 years ; mean disease 
duration, 12 ±  5.8 years; range,  5 – 30 years) were included. One patient was excluded 
because the evaluation three days after surgery could not be performed. A second patient was 
excluded because he had a positive CAM scale proving a confusional state at T3. This patient 
converted to dementia at six months. Table 1 shows the demographic characteristics of the 
study sample.   
 At 6 months, the UPDRS part III scores in the off-drug/on-stimulation and on-drug/on-
stimulation conditions significantly improved from the baseline (off-state) value respectively 
by 65 (range, 23 – 100) and 82 (range, 52–100) (P < 0.05). The severity of motor 
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fluctuations and dyskinesia as assessed by the UPDRS IV was significantly reduced by 62 
(range, -300 – 100) and 59 (range, -300 – 100), respectively. Dopaminergic drugs, 
expressed in dopa-equivalents, were reduced by 56 (range, 8.3 – 100), from 1093  342 
mg/day preoperatively to 487  308 mg/day at 6 months. The mean intensities were 2.9  0.3 
and 3.  0.4 V, pulse width 63.8  10.1 and 67.5  13.3 µs (respectively on the right and left 
sides), and frequency 141  25 Hz.  
Pre- and post-surgical values of semantic and phonemic VF are shown in Table 2. 
Number of total words was significantly reduced in the immediate post-operative period at T3 
for both fluency tasks. Semantic VF decreased by 44.4 ± 28.2  and phonemic VF by 34.3 ± 
33.4 (P < 0.05). Repeated post-operative neuropsychological testing demonstrated reliable 
improvement from T3 to T180 on verbal fluency tasks. Nevertheless, both semantic and 
phonemic VF at T180 remained significantly decreased in comparison to baseline scores, 
respectively by 3.4 ± 47.8 and 10.8 ± 32.1 (P < 0.05). 
 Nine patients fulfilled criteria for probable PDD at the end up follow-up, two of these 
within the first year following STN-DBS. New cases of PDD appeared throughout the follow-
up period which lasted from five years and three months to eight years. Once a patient was 
considered to have fulfilled the criteria for PDD, no later neuropsychological tests were 
administered. All of the patients categorized as PDD met criteria proposed by both Emre and 
the DSM-IV-TR. 
 First, multiple regression analysis showed that the reduction of phonemic VF at T3 
was an accurate independent predictor of the reduction of phonemic VF at T180 (F (3,20) = 
3.92, P <0.01).  Secondly, multiple regression analysis showed that age was an independent 
predictive factor for incident PDD (F (4,19) = 3.42, P <0.03). Other variables did not appear 
as independent predictors. 
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Discussion 
 In this study, we demonstrated that acute post-operative decline in phonemic VF can 
be predictive of a long-term phonemic VF deficit. However, the severity of this cognitive 
lesion is not correlated with the development of PDD. 
Meta-analyses have revealed that patients who underwent STN-DBS demonstrated 
mild but significant cognitive changes in verbal memory and executive functions and 
moderate decline in both semantic and phonemic VF [14-15]. Changes in phonemic and 
semantic VF are recognized as the most common cognitive decline following surgery [16-17]. 
Nevertheless, the mechanisms leading to cognitive changes following STN-DBS remain 
obscure. Since the intermediate and ventral parts of the STN are involved in both cognitive 
and limbic processes, it has been postulated that diffusion of the electrical current may affect 
cognitive performance, including VF [18]. Accordingly, at ventral contacts, more tissue 
activation inside the STN has been associated with decreased phonemic fluency performances 
[19]. Conversely, evidence has been accumulating suggesting that post-operative cognitive 
impairment could be more related to surgical procedure and its anatomical consequences than 
to the stimulation [8, 20-21]. 
 Previously, we reported an early and transient VF decline in eighteen PD patients just 
after STN implantation with the programmable pulse generator switched off (off-drug/ off-
stimulation) [8]. Since VF improves within the first 6 months following the surgical 
procedure, we hypothesized that the early VF impairment could above all reflect a cognitive 
microlesion effect. These findings corroborate a recent study that compared stimulation with 
implantation alone using the Saint Jude Medical constant-current device [20]. In this study, 
Okun et al. demonstrated that VF declines are related to the surgical procedure rather than the 
stimulation in STN-DBS. Another recent publication illustrated a greater decline in 
alternating VF performance in PD patients with STN-DBS as compared to patients that had 
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not been operated [21]. Taken together, these results are consistent with reports which have 
found that both intraoperative electrophysiological recordings and multiple trajectories of the 
definitive quadripolar electrode may contribute to deterioration in global cognition and 
memory function in PD patients after STN implantation [22-23]. Interestingly, recent studies 
have shown an increased risk of global cognitive decline and working memory performance 
after STN-DBS in PD when the chronic stimulation lead passes through the head of the 
caudate [22].   
In the present study, we found that the decline in phonemic VF was predictive of a 
continued decline in phonemic VF at six months. It is commonly believed that the temporal 
cortex supports word retrieval constrained by semantics while frontal regions support word 
retrieval constrained by phonology [24]. Thus, the microlesion effect along the trajectory of 
the electrode (passing through the dorsolateral prefrontal cortex) may be more pronounced on 
the phonemic VF task that relies solely on the frontostriatal network. As expected, the long-
term outcome of phonemic VF following surgical procedure correlated with the early decline 
synonymous of microlesion. 
Patients with PD have an increased risk of dementia compared to the general 
population. Thus, the likelihood of a patient with PD to develop dementia has been estimated 
at as high as forty percent with a cumulative prevalence of at least 75% ten years after 
diagnosis [25]. Cognitive impairment in PD is generally thought to affect predominantly 
executive and visuospatial functions but can touch various cognitive domains and has been 
found in patients at all stages of the disease. Patients with PDD present a dysexecutive profile 
of cognitive impairment where the most affected functions are attention, executive functions, 
and visuospatial functions, but memory can also be impacted [11].  
Even though STN-DBS is generally considered to be a cognitively safe procedure in 
well-selected patients, several studies show an accelerated cognitive decline in the months 
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following surgery, suggesting that a sub-group of patients may have a predisposition towards 
PDD following STN-DBS [26] However, few studies have tried to delineate predictive factors 
of PDD following STN-DBS. Notably, it has been reported that hippocampal atrophy is a 
predictor of dementia in PD patients converting to dementia after STN-DBS [26] Moreover, 
patients with advanced age, impaired baseline attention, and poorer levodopa response seem 
at greater risk for post-surgical cognitive decline [27, 28 ]. Since VF tests have been reported 
to be predictive of dementia in a community-based sample of non-operated PD patients, [29] 
we hypothesized that the long-term cognitive outcome following STN-DBS could be 
influenced by the severity of the early VF decline observed just after STN implantation. In 
our study, almost 35 (n = 9) of patients fulfilled criteria for probable PDD at the end up 
follow-up, 22 (n = 2) of these within the first year following STN-DBS. This incidence rate 
of dementia following STN-DBS is high when compared to previous studies with a similar 
follow-up period [26-27]. However, this result is consistent with the incidence of dementia 
observed in the natural course of PD, suggesting that PDD in our patients implanted with 
STN-DBS is most likely disease-related [25]. The fact that we were not able to clearly show 
that an early decline in VF (synonymous of microlesion) can predict which PD patients will 
develop dementia also corroborates this hypothesis.  
 In accordance with previous findings, older patients were more likely to develop 
dementia [25]. An interesting observation is that two patients who had performed well on 
cognitive tests, but had experienced hallucinations before the procedure, rapidly developed 
dementia relative to the rest of the population. Cognitive dysfunction has been noted after all 
types of surgery in older patients, and early post-operative cognitive decline was identified as 
an independent risk factor for persistent cognitive decline in one study [30]. However, there is 
little evidence that post-operative cognitive dysfunction leads to dementia or that surgery 
and/or anesthesia accelerate cognitive decline [31].  
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Three limitations of this study need to be pointed out: First, the population is small in 
size and relatively heterogeneous, in particular with regard to age. In addition, one patient was 
excluded for confusion at T3 and another patient was not tested at that same time point, 
further limiting the population size. Second, we considered the reduction of the number of 
words during VF analysis in the early post-operative as the optimal value to reflect the 
cognitive microlesion effect. However, we compared VF in two different conditions before 
and after surgery, i.e. with or without dopaminergic treatment. Levodopa treatment has often 
been shown to improve executive function in PD [32]. Therefore, as the fluency tasks 
necessitate a high degree of cognitive flexibility, we cannot exclude the involvement of abrupt 
withdrawal of levodopa treatment in the early post-operative VF decline. Accordingly, we 
previously described that post-operative VF impairment at T3 improves 10 days after surgery 
with resumed dopamine-replacement therapy [8]. Nevertheless, the a significant persistent 
impairment in verbal fluency in the on-drug condition compared to the baseline on-state 
pleads in favor of a microlesion effect. These results are in keeping with previous studies that 
failed to correlate VF decline and levodopa equivalent daily dose decrease after STN-DBS [8-
9, 15]. Moreover, other tests to explore executive dysfunction may have been considered as 
more pertinent but VF decline is recognized as the most common cognitive decline following 
STN-DBS surgery. Third, the length of follow-up was not entirely uniform. We consider 
however that over five years of follow-up is sufficient as any cases of dementia related to a 
stimulation-lead injury would have occurred early. Cases of dementia that occur multiple 
years after STN-DBS are most likely not related to the procedure and would be in any case 
indistinguishable from cases of dementia that are often part of the natural course of the 
disease.   




Our findings provide further information regarding the impact of the surgical 
procedure for STN-DBS on cognitive function over time. We demonstrated that the early 
decline in VF in the acute postoperative period can predict long-term VF deficits. Recently, 
STN-DBS was shown to improve quality of life in patients with early motor complications 
[33]. As teams are encouraged to implement DBS earlier in the course of the disease, more 
patients will be eligible for DBS before they are considered too old for the procedure. 
Therefore, the cognitive lesion effect merits to be studied in younger patients in order to better 











VF: Verbal fluency 
STN- DBS: Subthalamic nucleus deep brain stimulation 
PD: Parkinson disease 
VAS: Visual Analogic Scale 
UPDRS: Unified Parkinson Disease Rating Scale 
BMI: Body Mass Index 
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TABLE 1. Demographic characteristics at baseline  
Values are given as mean ± standard deviation.  
Dopaminergic drugs are expressed in dopa-equivalent daily dose. 
 
 
TABLE 2. Pre and post-surgical verbal fluency 
Values are given as mean ± standard deviation.  
Comparison of scores obtained before surgery (baseline on-state) and respectively at T3 and 
T180 after surgery used an analysis of variance for repeated measures (ANOVA). 
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*P < 0.05 compared to baseline. 
 
 
 
 
